Clinical Trials
34 trialsINS-ESCC-CT
Sichuan University
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
The Affiliated Hospital of Putian University
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
TD-NEOE3V3
Tang-Du Hospital
SCR-ESCC-01
Shanghai Chest Hospital
ILDR-03
Shantou University Medical College
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Tongji Hospital
ONTRESCC
Peking Union Medical College Hospital
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
The First Affiliated Hospital of Soochow University
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
ChineseAMS
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
The First Affiliated Hospital of Henan University of Science and Technology
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
Sinocelltech Ltd.
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
ECMTPneo
Peking University
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Positron Emission Tomography in Determining Stage of Esophageal Cancer
Alliance for Clinical Trials in Oncology
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
Radiation Therapy Oncology Group
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Memorial Sloan Kettering Cancer Center
Nimotuzumab
Fudan University